INO - Inovio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.43
-1.91 (-13.32%)
At close: 4:00PM EDT

12.16 -0.27 (-2.17%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close14.34
Open13.90
Bid12.15 x 1800
Ask12.25 x 2200
Day's Range12.10 - 14.32
52 Week Range1.92 - 19.36
Volume38,161,025
Avg. Volume43,007,426
Market Cap1.965B
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics
    Benzinga

    Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics

    The global economy is slowly emerging from lockdowns enacted to beat back the coronavirus. The pandemic isn't going anywhere, however, and hopes of a return to a semblance of normal rest heavily on the speedy development of vaccines against SARS-CoV-2, the virus that causes COVID-19.Fast-Tracking Vaccine Programs Vaccine development typically takes about 10-15 years, as it has to go through the same general pathway as that of drugs and biologics. With the advent of new classes of vaccines such as DNA and mRNA vaccines, development timelines could be tightened relative to traditional vaccines.Pandemics in recent history such as the MERS and SARS, also caused by coronaviruses, set in motion several R&D programs that have come in handy in today's scenario, as the new coronavirus shares 80% of its traits with its predecessors.Public-private partnerships have been forged to expedite vaccine programs. In mid-April, the National Institutes of Health announced a co-operative framework involving several biopharma companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the CDC, the FDA and the European Medicines Agency for expediting drug and vaccine research. Federal agencies have extended funding for companies with promising vaccine candidates in their pipeline, and this has given them the freedom to focus on research without having to worry about finances.The U.S. government recently launched the "Operation Warp Speed" project, which has among its objectives ensuring the availability of substantial quantities of a safe and effective vaccine for Americans by January 2021.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.US Government Backs 5 Vaccine Candidates In order to narrow the focus on the most deserving vaccine candidates, the Trump administration has shortlisted five from a crowded field and will likely make an announcement in this regard in the next few weeks, the New York Times reported.The shortlisted companies are, according to the Times: * Moderna Inc (NASDAQ: MRNA) * The Oxford University/AstraZeneca plc (NYSE: AZN) combination * Johnson & Johnson (NYSE: JNJ) * Merck & Co., Inc. (NYSE: MRK) * Pfizer Inc. (NYSE: PFE)Incidentally, Merck was a late entrant in the vaccine race, with the pharma giant announcing partnerships and deals to develop COVID-19 treatments and vaccines only recently.10 Vaccine Candidates In Clinics, 123 More In Labs A June 2 document from the World Health Organization showed that 10 vaccine candidates are in the clinics and 123 more are being evaluated in animal studies. Among the 10 vaccine candidates being tested in human studies, five are developed by Chinese firms or institutions. Here's an update on the 10 vaccines in the clinics:University Of Oxford/AstraZeneca The vaccine developed by the University of Oxford in collaboration with AstraZeneca was codenamed ChAdOx1 nCoV-19, a weakened version of a common cold virus that causes infections in chimpanzees.It has been genetically modified to make to prevent it from replicating in humans. After the university tied up with AstraZeneca, the vaccine candidate was renamed as AZD1222. AZD1222 is in a Phase 2/3 trial, with the university enrolling participants for the study in late May.Results from an ongoing Phase 1/2 trial could be available in mid-June; a university official was quoted as saying mid-May. AstraZeneca has received over $1 billion in BARDA funding for the development, production and delivery of the vaccine starting this fall.In late May, Adrian Hill, one of the lead investigators of the vaccine program, suggested the vaccine has only a 50% chance of succeeding, as the viral incidence receded in the community.Moderna Moderna, which is collaborating with NIAID for developing an mRNA vaccine, codenamed mRNA-1273, said recently it has dosed the first participant in a Phase 2 trial. The company also released interim data for its vaccine candidate from a NIAID-sponsored Phase 1 study, which showed dose-dependent increases in immunogenicity between prime and boost within the 25-microgram and 100-microgram dose levels. Moderna has prepped for scaling by forming an alliance with Swiss CDMO Lonza.See also: Inovio Analyst Watches Coronavirus Play 'From The Sidelines'CanSino Biological Inc./Beijing Institute of Biotechnology CanSino, which was the first to begin vaccine testing, announced last week the publication of Phase 1 data of its vaccine candidate Ad5 that showed most people developed immune responses.Yet he number of people developing neutralizing antibodies -- the ones that count for preventing infection -- was 75% among those who received the high dose and 50% among those who received the medium or low dose.A Phase 2 study of Ad5 was started in April and is underway. Ad5 is a genetically engineered adenovirus that delivers the gene encoding the spike protein of the SARS-CoV-2 into human cells.Wuhan Institute of Biological Products/Sinopharm The combo's vaccine candidate entered Phase 2 trials April 24, according to Xinhua. The Phase 1 trial is ongoing, the report said at that time. Sinopharm, one of the partners, seemed to suggest it will take one year of evaluation to determine the efficacy and safety of the inactivated vaccine candidate.Sinovac Sinovac, which began working on an inactivated vaccine candidate in January, said recently it is 99% confident in its vaccine candidate, codenamed CoronaVac. The candidate is in a Phase 1/2 trial. The company recently received $15 million in funding from private investors in lieu of a stake in the company.Novavax Novavax, Inc. (NASDAQ: NVAX) identified its vaccine candidate, codenamed NVX-CoV2373, in early April. The vaccine candidate is a stable prefusion protein made using the company's proprietary nanoparticle technology, with Matrix-M adjuvant incorporated to enhance the immunity response of the vaccine.The company said May 25 it enrolled the first participant in the Phase 1 portion of a Phase 1/2 study it has initiated, with results from the Phase 1 portion expected in July. In mid-May, the company announced an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations. On Wednesday, AGC Biologics said it has been tasked with manufacturing Matrix-M adjuvant by Novavax.Beijing Institute Of Biological Products/Sinopharm State-affiliated Beijing Institute of Biological Products, which is developing an inactivated vaccine in a Phase 1/2 trial, has started the Phase 2 trial, a post on the WeChat account of the Chinese state-owned Assets Supervision and Administration Commission said. Pfizer/BioNTech Pfizer is collaborating with German biopharma BioNTech SE - ADR (NASDAQ: BNTX) for vaccine development. BioNTech is evaluating four vaccine candidates in its BNT162 program. These are mRNA vaccines combined with a lipid nanoparticle formulation. BNT162 is being tested in separate Phase 1/2 trials in Europe and the U.S. Pfizer will be vested with the responsibility of scaling up at risk.Institute Of Medical Biology, Chinese Academy Of Medical Sciences In mid-May, the institute received approval for commencing a Phase 1 study.Inovio Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine codenamed INO-4800, said in its May 11 earnings release it has completed enrollment in a Phase 1 study.It anticipates commencing a Phase 2/3 efficacy trial in summer, subject to regulatory approval. Inovio has received funding from the CEPI as well as the Bill & Melinda Gates Foundation.Among others, J&J, which has identified a lead vaccine candidate, plans a clinical study by September. The company expects the first batches of a vaccine to be available for emergency use authorization by early 2021.Several other companies are also in the fray, including Sorrento Therapeutics Inc (NASDAQ: SRNE), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY).Related Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley See more from Benzinga * The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study * The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To 0M In Biotechs * Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Why Inovio Pharmaceuticals Stock Sank Today
    Motley Fool

    Why Inovio Pharmaceuticals Stock Sank Today

    Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sinking 12.8% lower as of 3:27 p.m. EDT on Wednesday. Inovio's shares slipped earlier in the day following comments that Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), made in an interview with JAMA editor Howard Bauchner. Fauci stated that he was concerned that COVID-19 vaccines likely won't provide a long period of immunity.

  • Analyst Sounds the Valuation Alarm Bell on Inovio’s Hot Stock
    TipRanks

    Analyst Sounds the Valuation Alarm Bell on Inovio’s Hot Stock

    Without a doubt, Inovio Pharmaceuticals (INO) is one of the year’s success stories. Heading into 2020, INO shares were going for $3.30 apiece. The stock is now priced at $13.30, an increase of a hefty 303%.As for how the biotech accumulated such impressive gains, the company has positioned itself as one to watch with its COVID-19 DNA vaccine candidate, INO-4800.However, even as investors’ optimism surges, some remain more skeptical. Among the skeptics is RBC Capital analyst Gregory Renza.The 5-star analyst rates INO shares a Sector Perform (i.e. Hold) along with a $10 price target. In other words, Renza expects shares to come down by a considerable 25% over the next year. (To watch Renza’s track record, click here)That’s not to say Renza thinks Inovio is doing anything particularly wrong. The promising preclinical data for the biotech’s COVID-19 DNA vaccine candidate, and overall progress - INO-4800 is currently in a Phase 1 trial with interim data expected in June and initiation of a larger Phase 2/3 trial expected in the summer – has impressed Renza. That being said, the analyst remains apprehensive when considering Inovio’s chances of bringing a viable solution to market.Renza said, “We are encouraged by the swift progress of the program, and increased our PoS (probability of success) for the accelerated development timeline scenario to 70% (from 50%) though we maintain our 25% level of ultimate success, and continue to monitor the development of the INO-4800 story and larger landscape.”Furthermore, after speaking to key opinion leaders (KOLs), Renza is concerned with another issue. Although encouraged by the early data, the KOLs have expressed doubt regarding the 12-18 month timeline for the vaccine, as more data will be required to “understand the protection levels of immune responses and the physiology of the responses.” Additionally, as highlighted by one KOL, the 12-18-month timeline “could be deemed aggressive, and can only be achieved if 'everything goes well’.”Overall, Renza’s colleagues take a more positive view. The consensus breakdown of 5 Buys and 3 Holds coalesce into a Moderate Buy consensus rating. With an average price target of $16.71, the analysts forecast possible upside of 27% over the next 12 months. (See Inovio stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Why Inovio Shares Rose 22.6% in May
    Motley Fool

    Why Inovio Shares Rose 22.6% in May

    Inovio Pharmaceuticals (NASDAQ: INO) shares climbed 22.6% in May, according to data from S&P Global Market Intelligence, as investors cheered the rapid development of its coronavirus vaccine and as the company published positive preclinical data. Inovio in late April said it completed enrollment of 40 healthy volunteers in a phase 1 trial for its coronavirus vaccine and said it expects preliminary data in late June. The company last month announced the publication of preclinical data showing strong neutralizing antibody and T-cell immune responses in animal models.

  • Inovio Analyst Watches Coronavirus Play 'From The Sidelines'
    Benzinga

    Inovio Analyst Watches Coronavirus Play 'From The Sidelines'

    Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) is not an outright buy at this point in time, according to an analyst at Piper Sandler.The Inovio Analyst Christopher Raymond maintained a Neutral rating on Inovio shares with an $8 price target. The Inovio Thesis The 12-month overall survival data Inovio presented for its DNA cancer vaccine INO-5401 in glioblastoma multiforme -- a deadly form of brain cancer -- at the ASCO made the benefit less clear, Raymond said in a Monday note. (See his track record here.) The vaccine is being studied in a Phase 2 single-arm study in newly diagnosed GBM patients following gross total resection and in combo with radiotherapy, temozolomide and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo, he said. "While the data have demonstrated that a subset of patients had a T cell response to treatment, there is still uncertainty over INO-5401's individual therapeutic benefit." Longer-term and randomized data for the vaccine would help Piper Sandler feel more confident in the program, Raymond said.An overall survival update due later this year is a key catalyst for the program, the analyst said. Given the uncertainty, he said INO-5401 remains an unmodeled opportunity at this point.Piper Sandler sees several upcoming catalysts for Inovio, including first-in-human data from INO-4800 due later this month and an update on potential funding for the program to support further development."However, given the ongoing volatility surrounding this name over COVID-19 efforts, we prefer to watch this story play out from the sidelines," Raymond said. INO Price Action At last check, Inovio shares were down 5.85% at $13.99. Related Links:The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Latest Ratings for INO DateFirmActionFromTo May 2020BenchmarkInitiates Coverage OnBuy Apr 2020StifelMaintainsBuy Apr 2020HC Wainwright & Co.ReiteratesBuy View More Analyst Ratings for INO View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant * The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas * The Week Ahead In Biotech: ASCO Presentations In The Spotlight(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
    Motley Fool

    Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?

    The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.

  • Why Moderna Stock Is Still Only Good for Speculators
    InvestorPlace

    Why Moderna Stock Is Still Only Good for Speculators

    Speculation surrounding the novel coronavirus has taken over the stock market. Hope for a cure or, better yet, a vaccine, is driving traders into frenzies. Much of the action is centered around Moderna (NASDAQ:MRNA) and MRNA stock.Source: Shutterstock While the company had just $8.3 million in revenue for the March quarter, it entered trade May 29 with a market cap of $20.6 billion.MRNA stock has been on fire for months. In February, the shares cost $18. It was the release of Phase 1 data earlier this month that sent traders into a frenzy. That showed, as expected, that antibodies against the virus were produced in test subjects. The company also said it was rapidly scaling up production.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTraders who had been buying Moderna rumors sold the news. The shares have since fallen from the mid-80's to the mid-50's. Why Moderna?Nothing has gone wrong, from a scientific standpoint. It's just that there are no guarantees Moderna has the winning lottery ticket.There are now 28 different vaccines being researched around the world, with eight in some type of clinical trial. There are vaccines being tested in England, in China and in Australia. Two other publicly traded U.S. companies, Pfizer (NYSE:PFE) and Inovio Pharmaceuticals (NASDAQ:INO), have Covid-19 vaccine candidates in trial. Novavax (NASDAQ:NVAX), Johnson & Johnson (NYSE:JNJ), and Altimmune (NASDAQ:ALT) are all doing pre-clinical work. So are Merck (NYSE:MRK), GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY). * 7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure Moderna just got there first, with the most publicity. It announced funding on Jan. 23. It's working with the National Institute of Allergy and Infectious Diseases (NIAID), headed by the now-famous Dr. Anthony Fauci. It won an invitation to the White House to talk about its candidate, mRNA-1273. Why Not Moderna?The problem is that vaccines are hard. It's not enough to create antibodies against the disease. A vaccine must stop the spread safely across millions or (in this case) billions of doses.Safety is one issue. Four of the 45 people tested in the Phase 1 study developed reactions to the Moderna vaccine. One 29-year old tweeted that he got a 103 degree fever. He said his dose was 10 times what other patients got, and he didn't go to a hospital in fear of triggering "anti-vax" people.Efficacy is a second issue. Only eight of the subjects produced binding antibodies. Only four were sampled for neutralizing antibodies. The level of T-Cell generation, a measure of how the body is attacking the virus, wasn't mentioned.Moderna's own actions are also an issue. The company announced a $1 billion secondary offering right after its Phase 1 results came out. Some executives sold shares within days. Moderna is moving directly into a Phase 3 study, and mass production, while its Phase 1 is still being evaluated.All these actions have raised suspicions among people who know both science and market valuations. The Bottom Line on MRNA StockThis is my fourth piece on Moderna in six months.I was very positive about MRNA stock when it came public in December. Its methodology, using Messenger RNA, impressed me. In April, I called Moderna "the greatest coronavirus speculation." The problem is success against Covid-19 is now built-into the stock price. Success is far from guaranteed. There are many other horses in this race. It's far from clear how profitable this vaccine will be.It's possible mRNA-1273 could be the start of a business that goes on for decades. It's possible that mRNA-1273 proves Moderna's methodology and it becomes one of the world's great companies. It's also possible that mRNA-1273 fails in Phase 3.There are too many known unknowns for me to recommend investing in MRNA stock at its present price. But you're welcome to speculate.Dana Blankenhorn has been a financial journalist since 1978. His latest book is Technology's Big Bang: Yesterday, Today and Tomorrow with Moore's Law, essays on technology available at the Amazon Kindle store. Follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in JNJ. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * The Huge Story for 2020 & Beyond That You Aren't Hearing About * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * The 1 Stock All Retirees Must Own The post Why Moderna Stock Is Still Only Good for Speculators appeared first on InvestorPlace.

  • Investopedia

    Novavax and Merck Fuel COVID-19 Vaccine Hopes

    Novavax has begun human trials, and Merck has joined the race with the acquisition of Themis and collaboration with non-profit IAVI.

  • An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race
    Yahoo Finance

    An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race

    Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.

  • Inovio Can Climb Higher, Says Top Analyst
    TipRanks

    Inovio Can Climb Higher, Says Top Analyst

    The race to develop a vaccine against COVID-19 is charging full speed ahead. Yesterday, Inovio Pharmaceuticals (INO) released promising preclinical data for the biotech’s COVID-19 DNA vaccine candidate, INO-4800. Investors have high hopes for the vaccine maker and have sent the stock soaring by over 332% so far this year. The results, published in Nature Communications, showed INO-4800 elicited strong binding and neutralizing antibody responses in addition to high-level T cell responses in mice and guinea pigs. INO-4800 targets the major antigen spike protein of the SARS-CoV-2 virus, which causes COVID-19, and is currently in a Phase 1 trial. 40 healthy volunteers are taking part, with interim data expected in June. With data in hand, Inovio will approach the FDA for authorization to move forward with a Phase 2/3 trial, which it hopes to initiate in July or August. The company expects to recruit 2,000 frontline healthcare workers for the Phase 2/3 study. “We believe data from this randomized trial, if positive, could allow the company to file for emergency regulatory approval for INO-4800,” said H.C. Wainwright’s Ram Selvaraju. Additionally, Inovio will examine the vaccine in larger animals including rabbits and monkeys. The company will conduct "challenge" studies, which involve giving the virus to an animal and then seeing if the vaccine prevents the infection. “In our view, these animal data bode well for the upcoming data from multiple animal challenge studies and data readout from the ongoing Phase 1 study in June,” Selvaraju added. It should come as no surprise, then, that the 5-star analyst reiterated a Buy rating on Inovio, accompanied by a $17 price target. There’s upside of 22% in the cards, should the target be met over the next 12 months. (To watch Selvaraju’s track record, click here) Over the last three months, 8 analysts have thrown the hat in with a view on the vaccine maker’s prospects, with 5 recommending Buy and 3 saying Hold. This makes the consensus rating a Moderate Buy. Overall, the Street sees upside potential of 18% ahead, as the average price target comes in at $16.57. (See Inovio stock analysis on TipRanks)

  • Fmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development
    Yahoo Finance Video

    Fmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development

    Vanderbilt University School of Medicine,Professor of Medicine in the Division of Infectious Diseases Dr. William Schaffner joins Yahoo Finance’s Seana Smith to discuss the coronavirus, as a quarter of Americans say they are nervous about a vaccine, according to a new Reuters/Ipsos poll.

  • Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline
    Benzinga

    Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline

    A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO), sell-side analysts lined up behind the company. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The Inovio Analysts Benchmark analyst Aydin Huseynov initiated shares of Inovio with a Buy rating and $28 price target. H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $17 price target.Inovio Shares To Benefit From Likelihood of Financing For COVID Vaccine, Benchmark Says Inovio's SARS-CoV-2 vaccine candidate INO-4800 has a meaningful chance of progressing to Phase 2/3 in the July-August timeframe and securing the necessary financing from the government or nonprofits, Benchmark analyst Huseynov said in a note.Noting that Inovio has a pipeline of vaccine candidates for various infectious diseases such as HIV, Ebola, MERS and Zika, the analyst said the company will get sufficient financial support for every promising vaccine candidate, including INO-4800."Also, Inovio's DNA plasmid platform has commercially and clinically attractive HPV-targeting and immuno-oncology drug candidates that may drive INO's shareholder value longer term." The higher probability of Inovio securing external non-dilutive financing to move INO-4800 further into the clinic is likely to help its share price, Huseynov said.The analyst also noted that the company has promising late-stage oncology assets, VGX-3100 and INO-5401, with potential launches in 2023 and combined risk-unadjusted peak 2035 sales of $1.4 billion.See also: AstraZeneca Receives Over B In BARDA Funding For Coronavirus Vaccine Preclinical Data Bode Well For Phase 1 Data Due In June, HC Wainwright Says Preclinical studies showed that vaccination with INO-4800 generated binding and neutralizing antibodies as well as T cell responses in mice and guinea pigs, H.C. Wainwright analyst Selvaraju said.The fact that researchers were able to demonstrate neutralizing activity of the vaccine using three separate neutralization assays is remarkable, the analyst said. Additionally, these antibodies were detected in the lungs of the vaccinated animals, and high levels of Spike-specific T cell responses were observed, he said. "In our view, these animal data bode well for the upcoming data from multiple animal challenge studies and data readout from the ongoing Phase 1 study in June." INO Price Action Inovio shares were trading down 9.86% at $14.23 at the time of publication Thursday.Related Link: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive Latest Ratings for INO DateFirmActionFromTo May 2020BenchmarkInitiates Coverage OnBuy Apr 2020StifelMaintainsBuy Apr 2020HC Wainwright & Co.ReiteratesBuy View More Analyst Ratings for INO View the Latest Analyst Ratings See more from Benzinga * Inovio Publishes Positive Animal Testing Data For Coronavirus DNA Vaccine * Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Citron Questions Inovio's 'Robust' Preclinical Coronavirus Vaccine Announcement, Sees 90% Downside Ahead
    Benzinga

    Citron Questions Inovio's 'Robust' Preclinical Coronavirus Vaccine Announcement, Sees 90% Downside Ahead

    Inovio Pharmaceuticals Inc (NASDAQ: INO) said Wednesday that positive preclinical data for its DNA vaccine for the SARS-CoV-2 has been published in a peer-reviewed journal, sending its shares higher.Inovio's Preclinical Data News Stale? Following the announcement, short seller Citron Research came down heavily on the company, stating in its report that the announcement is not a fresh one and calling for the SEC to halt trading in the stock. "We immediately began preclinical testing and small-scale manufacture and have already shared robust preclinical data with our public and private partners," Inovio's CEO Dr. Joseph Kim said in a March 3 release.Citron Sees Tall But Empty Claims From Inovio Citron also said the situation is deja vu. Inovio has been in the habit of sharing press releases highlighting positive animal testing data for "every disease it researches" without producing a single commercial product in 40 years, Citron said in the report, lining up Inovio's previous releases as evidence for its claim."Simply put, Inovio is nothing but over 40 years of 'robust' data without a single product to market," Citron said.Benzinga has contacted Inovio for comment on the Citron report. About 90% Downside Likely For Inovio, Short Seller Says In a tweet, Citron assigned a $2 price target for the company, which represents about 86% downside from Tuesday's closing price.> $INO Company should be halted as they have no shame in this time of crisis. Read Citron to see how $INO issued "robust preclinical" data in EVERY situation that has resulted in 0 products to market. Company has become a full stock promotion. Tgt price $2> > -- Citron Research (@CitronResearch) May 20, 2020Inovio shares were trading 8.73% higher at $15.83 at the time of publication Wednesday. Related Links: The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test See more from Benzinga * Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand * Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Coronavirus update: Global case tally at 4.9 million as Trump considers travel ban on Brazil after big jump in death toll
    MarketWatch

    Coronavirus update: Global case tally at 4.9 million as Trump considers travel ban on Brazil after big jump in death toll

    The number of global cases of the coronavirus that causes COVID-19 rose to 4.9 million on Wednesday and Brazil suffered its worst fatalities since the start of the outbreak, prompting President Donald Trump to say he may bar entry to flights from Brazil.

  • Barrons.com

    Another Biotech Stock Gets a Lift From Encouraging, but Early, Vaccine Data

    Inovio, like Moderna, is conducting a Phase 1 human trial of its vaccine, with 40 volunteers enrolled. It plans to report initial results on safety and immune responses in that study in late June.

  • Inovio Pops Almost 10% on ‘Positive’ Preclinical Results For Its Covid-19 Vaccine
    SmarterAnalyst

    Inovio Pops Almost 10% on ‘Positive’ Preclinical Results For Its Covid-19 Vaccine

    Inovio Pharmaceuticals (INO) surged almost 10% after the company said that preclinical study data results of its potential vaccine candidate showed “robust” neutralizing antibody and T cell immune responses against coronavirus.Shares rose 9.5% to $15.94 in midday U.S. trading. The value of the stock has this year gone up five-fold with investors excited about Inovio’s potential Covid-19 vaccine INO-4800. The vaccine drug candidate targets the major antigen Spike protein of SARS-CoV-2 virus, which causes Covid-19 disease."These positive preclinical results from our Covid-19 DNA vaccine not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700,” said Kate Broderick, Inovio's Senior VP of R&D. “The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials."The study found that vaccination with INO-4800 generated robust binding and neutralizing antibody as well as T cell responses in mice and guinea pigs. What’s more Inovio now expects in June to receive preliminary safety and immune responses data from Phase 1 clinical trial.“We are planning to utilize these positive preclinical results along with our upcoming animal challenge data and safety and immune responses data from our Phase 1 studies to support rapidly advancing this summer to a large, randomized Phase 2/3 clinical trial,” said Dr. J. Joseph Kim, Inovio’s President & CEO.Inovio is currently preparing to initiate a larger Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred. Phase 2/3 trial is now planned to start in July or August pending regulatory approval.Five-star analyst Jason McCarthy at Maxim Group this month raised his price target on the stock to $18 from $12 and maintained a Buy rating.“Inovio and its deep pipeline of DNA vaccines for infectious diseases, including other coronaviruses, has demonstrated safety and induced robust immune responses, more than any in the space, in our view,” McCarthy wrote in a note to investors. “Yet, from a valuation perspective INO lags its nucleic-acid vaccine peers MRNA and BNTX.The Street has a cautiously optimistic outlook on Inovio, with a Moderate Buy consensus based on 4 Buys and 3 Holds. As share prices have skyrocketed so quickly, the $14.14 average analyst price target now indicates more than 10% downside potential. (See Inovio stock analysis on TipRanks).Related News: Bluebird Prices New Shares At $55, Seeks To Raise $500 Million Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval More recent articles from Smarter Analyst: * Boeing Cuts 6,770 Jobs In U.S.; CFRA Upgrades Stock To Buy   * Google Faces Arizona Lawsuit Over ‘Unfair’ Location Data Storing * Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses; Top Analyst Ramps Up PT To $61 * Hertz Sinks 11% After-Hours As Carl Icahn Sells Stake At $1.8B Loss

  • Benzinga

    Price Over Earnings Overview: Inovio Pharmaceuticals

    In the current session, Inovio Pharmaceuticals Inc. (NASDAQ: INO) is trading at $16.17, after a 11% rise. Over the past month, the stock increased by 38.12%, and in the past year, by 397.66%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 16.48%.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Inovio Pharmaceuticals has a better P/E ratio of 0.0 than the aggregate P/E ratio of 0.0 of the biotechnology industry. Ideally, one might believe that Inovio Pharmaceuticals might perform better in the future than it's industry group, but it's probable that the stock is overvalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * 16 Healthcare Stocks Moving In Wednesday's Pre-Market Session * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Inovio Publishes Positive Animal Testing Data For Coronavirus DNA Vaccine
    Benzinga

    Inovio Publishes Positive Animal Testing Data For Coronavirus DNA Vaccine

    With the Street and experts divided on rival Moderna Inc's (NASDAQ: MRNA) recently released interim Phase 1 readout, Inovio Pharmaceuticals Inc (NASDAQ: INO) released positive preclinical data for its SARS-CoV-2 vaccine candidate INO-4800.What Happened?Pennsylvania-based Inovio announced publication of data from animal testing of INO-4800 in the peer-reviewed journal "Nature Communications" showing robust neutralizing antibody and T-cell immune responses against the coronavirus mice and guinea pigs.The article was authored by Inovio scientists and collaborators from the Wistart Institute, the University of Texas, Public Health England, Fudan University and Advaccine."These positive preclinical results from our COVID-19 DNA vaccine not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700," said Dr. Kate Broderick, SVP of R&D and Team Lead for COVID-19 vaccine at Inovio.Data also showed antibodies were detected in the lungs of the vaccinated animals, which could be important in providing protection from SARS-CoV-2. Additionally, high levels of Spike-specific T-cell responses were observed with INO-4800 vaccination, underlining its importance in mediating protection from the virus infection.Why It MattersWith the COVID-19 pandemic bringing the world to a standstill, biopharma companies and institutions have plunged headlong into developing a treatment or vaccine to counter the virus.Inovio was touted to be one of the frontrunners for a vaccine against the virus. Moderna reported Monday positive interim Phase 1 data for its mRNA vaccine candidate mRNA-1273. STAT News reported, citing experts, data from eight subjects is not adequate to authenticate the efficacy and safety results released by the company.What's Next?Inovio said these positive preclinical results along with its upcoming animal challenge data, and safety and immune responses data from its Phase 1 studies support rapid advancement of the INO-4800 this summer to a large, randomized Phase 2/3 clinical trial.In pre-market trading Wednesday, Inovio shares were higher by 14.08% to $16.61.Related Links:A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleySee more from Benzinga * Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand * Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • U.S. Stocks Set To Open Higher On Renewed Optimism
    FX Empire

    U.S. Stocks Set To Open Higher On Renewed Optimism

    S&P; 500 futures are up more than 1% in premarket trading as Inovio Pharmaceuticals reports promising results for its COVID-19 vaccine.

  • MarketWatch

    Inovio's stock gains on early data testing its COVID-19 vaccine in animals

    Shares of Inovio gained 22.8% in premarket trading on Wednesday after the company said its COVID-19 vaccine candidate demonstrated neutralizing antibodies in animals. The data, published in Nature Communications, is from a preclinical study, meaning it does not include information about how the investigational vaccine reacts in humans but in mice and guinea pigs. Inovio is currently conducting a Phase 1 clinical trial testing the DNA vaccine candidate in people; early data from that study is expected to be announced in June. "The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials," Dr. Kate Broderick, Inovio's team lead for COVID-19 vaccine development, said in a news release. There are no proven vaccines that prevent against infections with COVID-19. Moderna Inc. announced early positive results from its Phase I trial testing a vaccine candidate in people on Monday. Inovio's stock is up 341.2% year-to-date, while the S&P 500 is down 9.5%.

  • Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs
    Reuters

    Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs

    "We saw antibody responses that do many of the things we would want to see in an eventual vaccine," said Dr. David Weiner, director of the vaccine and immunotherapy center at the Wistar Institute, which has collaborated with Inovio. There are currently no approved treatments or vaccines for COVID-19, the disease caused by the new coronavirus, with governments, drugmakers and researchers working on around 100 vaccine programs. Many other drugmakers including Moderna Inc, Pfizer Inc, Johnson & Johnson, Sanofi and AstraZeneca Plc are also in various stages of vaccine development.

  • Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'
    Yahoo Finance Video

    Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'

    Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.